Synthesis, Activity, and Pharmacophore Development for Isatin-β-thiosemicarbazones with Selective Activity toward Multidrug-Resistant Cells

被引：152

作者：

Hall, Matthew D. ^{[1
]}

Salam, Noeris K. ^{[2
]}

Hellawell, Jennifer L. ^{[1
]}

Fales, Henry M. ^{[3
]}

Kensler, Caroline B. ^{[3
]}

Ludwig, Joseph A. ^{[4
]}

Szakacs, Gergely ^{[5
]}

Hibbs, David E. ^{[2
]}

Gottesman, Michael M. ^{[1
]}

机构：

[1] NCI, Cell Biol Lab, NIH, Bethesda, MD 20892 USA

[2] Univ Sydney, Fac Pharm, Pharmaceut Chem Div, Grp Biomol Struct & Informat, Sydney, NSW 2006, Australia

[3] NHLBI, Lab Appl Mass Spectrometry, NIH, Bethesda, MD 20892 USA

[4] Univ Texas MD Anderson Canc Ctr, Dept Sarcoma Med Oncol, Houston, TX 77030 USA

[5] Hungarian Acad Sci, Inst Enzymol, H-1113 Budapest, Hungary

来源：

JOURNAL OF MEDICINAL CHEMISTRY | 2009年 / 52卷 / 10期

基金：

美国国家卫生研究院; 澳大利亚研究理事会;

关键词：

PRIMARY CYTOTOXICITY EVALUATION; RIBONUCLEOTIDE REDUCTASE; 3-AMINOPYRIDINE-2-CARBOXALDEHYDE THIOSEMICARBAZONE; IRON CHELATORS; PHASE-I; CANCER; INHIBITOR; DISCOVERY; TRANSPORTERS; DERIVATIVES;

D O I：

10.1021/jm800861c

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

We have recently identified a new class of compounds that selectively kill cells that express P-glycoprotein (P-gp, MDR1), the ATPase efflux pump that confers multidrug resistance on cancer cells. Several isatin-beta-thiosemicarbazones from our initial study have been validated and a range of analogues synthesized and tested. A number demonstrated improved MDR1-selective activity over the lead, NSC73306 (1). Pharmacophores for cytotoxicity and MDR1 selectivity were generated to delineate the structural features required for activity. The MDR1-selective pharmacophore highlights the importance of aromatic/hydrophobic features at the N4 position of the thiosemicarbazone and the reliance on the isatin moiety as key bioisosteric contributors. Additionally, a quantitative structure-activity relationship (QSAR) model that yielded a cross-validated correlation coefficient of 0.85 effectively predicts the cytotoxicity of untested thiosemicarbazones. Together, the models serve as effective approaches for predicting structures with MDR1-selective activity and aid in directing the search for the mechanism of action of 1.

引用

页码：3191 / 3204

页数：14

共 45 条

[1] Agrawal K C, 1978, Prog Med Chem, V15, P321, DOI 10.1016/S0079-6468(08)70259-5
[2] [Anonymous], MACROMODEL VERS 9 1
[3] ANTHOLINE W, 1977, MOL PHARMACOL, V13, P89
[4] Sunitinib maleate
Atkins, M
Jones, CA
Kirkpatrick, P
[J]. NATURE REVIEWS DRUG DISCOVERY, 2006, 5 (04) : 279 - 280
[5] A HISTORY OF THE DISCOVERY AND CLINICAL-APPLICATION OF ANTIVIRAL DRUGS
BAUER, DJ
[J]. BRITISH MEDICAL BULLETIN, 1985, 41 (04) : 309 - 314
[6] Synthesis of novel 5-substituted indirubins as protein kinases inhibitors
Beauchard, Anne
Ferandin, Yoan
Frere, Stephane
Lozach, Olivier
Blairvacq, Melina
Meijer, Laurent
Thiery, Valerie
Besson, Thierry
[J]. BIOORGANIC & MEDICINAL CHEMISTRY, 2006, 14 (18) : 6434 - 6443
[7] The wide pharmacological versatility of semicarbazones, thiosemicarbazones and their metal complexes
Beraldo, H
Gambino, D
[J]. MINI-REVIEWS IN MEDICINAL CHEMISTRY, 2004, 4 (01) : 31 - 39
[8] BROCKMAN RW, 1956, CANCER RES, V16, P167
[9] OXIDATIVE REACTIONS OF HYDRAZINES .4. ELIMINATION OF NITROGEN FROM 1,1-DISUBSTITUTED-2-ARENESULFONHYDRAZIDES
CARPINO, LA
[J]. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 1957, 79 (16) : 4427 - 4431
[10] Pharmacophore-based discovery of ligands for drug transporters
Chang, Cheng
Ekins, Sean
Bahadduri, Praveen
Swaan, Peter W.
[J]. ADVANCED DRUG DELIVERY REVIEWS, 2006, 58 (12-13) : 1431 - 1450

← 1 2 3 4 5 →